Exelixis | EXEL - Debt


Exelixis reported $179.84M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Bayer EUR 39.39B 1.31B Mar/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Cytokinetics USD 858.06M 199.93M Jun/2025
Eisai JPY 187.52B 31.58B Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Genmab DKK 148M 5M Jun/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025